UBS AM’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-25,836
| Closed | -$2.35M | – | 2719 |
|
|
2023
Q2 | $2.35M | Hold |
25,836
| – | – | ﹤0.01% | 1574 |
|
|
2023
Q1 | $2.35M | Buy |
25,836
+2,028
| +9% | +$184K | ﹤0.01% | 1574 |
|
|
2022
Q4 | $904K | Buy |
23,808
+1,540
| +7% | +$58.5K | ﹤0.01% | 1895 |
|
|
2022
Q3 | $560K | Sell |
22,268
-10,159
| -31% | -$255K | ﹤0.01% | 2295 |
|
|
2022
Q2 | $985K | Buy |
32,427
+3,742
| +13% | +$114K | ﹤0.01% | 1974 |
|
|
2022
Q1 | $940K | Buy |
28,685
+2,643
| +10% | +$86.6K | ﹤0.01% | 2184 |
|
|
2021
Q4 | $687K | Sell |
26,042
-5,063
| -16% | -$134K | ﹤0.01% | 2406 |
|
|
2021
Q3 | $3.13M | Sell |
31,105
-849
| -3% | -$85.4K | ﹤0.01% | 1606 |
|
|
2021
Q2 | $4.52M | Sell |
31,954
-6,074
| -16% | -$860K | ﹤0.01% | 1421 |
|
|
2021
Q1 | $3.79M | Sell |
38,028
-372
| -1% | -$37.1K | ﹤0.01% | 1466 |
|
|
2020
Q4 | $4.75M | Buy |
38,400
+5,597
| +17% | +$692K | ﹤0.01% | 1320 |
|
|
2020
Q3 | $3.2M | Buy |
32,803
+839
| +3% | +$81.7K | ﹤0.01% | 1339 |
|
|
2020
Q2 | $4.99M | Buy |
31,964
+8,477
| +36% | +$1.32M | ﹤0.01% | 1115 |
|
|
2020
Q1 | $3.39M | Buy |
23,487
+1,502
| +7% | +$217K | ﹤0.01% | 1209 |
|
|
2019
Q4 | $4.49M | Buy |
21,985
+2,360
| +12% | +$482K | ﹤0.01% | 1233 |
|
|
2019
Q3 | $1.58M | Buy |
19,625
+4,560
| +30% | +$366K | ﹤0.01% | 1725 |
|
|
2019
Q2 | $1.42M | Buy |
15,065
+4,692
| +45% | +$443K | ﹤0.01% | 1750 |
|
|
2019
Q1 | $887K | Buy |
10,373
+1,632
| +19% | +$139K | ﹤0.01% | 1871 |
|
|
2018
Q4 | $490K | Hold |
8,741
| – | – | ﹤0.01% | 2003 |
|
|
2018
Q3 | $715K | Buy |
+8,741
| New | +$715K | ﹤0.01% | 1937 |
|
|
2018
Q2 | – | Sell |
-175,096
| Closed | -$3.59M | – | 2812 |
|
|
2018
Q1 | $3.59M | Sell |
175,096
-8,901
| -5% | -$183K | ﹤0.01% | 1246 |
|
|
2017
Q4 | $5.21M | Sell |
183,997
-2,793
| -1% | -$79.1K | ﹤0.01% | 1097 |
|
|
2017
Q3 | $5.81M | Buy |
+186,790
| New | +$5.81M | 0.01% | 1037 |
|